Shots:

• The P-III (FRESCO-2) MRCT study evaluates fruquintinib + BSC vs PBO + BSC in 691-patient with advanced, refractory m-CRC
• The study showed a 34% reduction in risk of death, improvement in disease control with the risk of disease progression or death reduced by 68% & improvement in OS & PFS; m-OS (7.4mos. vs 4.8mos.), m-PFS (3.7mos. vs 1.8mos.), DCR was 55.5% vs 16.1%, and the median duration of follow-up was ~11mos. The safety profile was consistent with prior reported fruquintinib studies, grade ≥3 AEs (62.7% vs 50.4%)
• Fruquintinib is a highly selective & potent oral inhibitor of VEGFR-1, 2 & 3 & is designed to increase kinase selectivity to reduce toxicities that are off-target, increase tolerance & give more reliable target coverage

Ref: Globenewswire | Image: HUTCHMED